Kinrix + MMR II

This combination regimen consists of the co-administration of GlaxoSmithKline's **Kinrix** (DTaP-IPV) and Merck's **MMR II** (Measles, Mumps, and Rubella Virus Vaccine Live). Kinrix is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age. MMR II is a live virus vaccine for vaccination against measles, mumps, and rubella. The co-administration of these vaccines is a standard clinical practice during the preschool booster visit, and clinical trials (such as NCT00324701) have evaluated the safety and immunogenicity of concurrent administration at separate injection sites to ensure that immune responses to each component remain robust and non-inferior to separate administration.

Brand names

KinrixMMR II

Other names

MMRII-GlaxoSmithKline-diphtheria-tetanus-pertussis-poliomyelitisDTaP-IPV + MMRMeasles, Mumps, and Rubella Virus Vaccine Live + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine